Industry and regulators signal a smarter, collaborative era for supplement oversight
While the industry has spent years bracing for and fending off a heavier regulatory hand, what it heard…
Medicare spending far less than expected on new Alzheimer’s drugs
Bob Herman covers health insurance, government programs, hospitals, physicians, and other providers — reporting on how money influences…
3 Stocks Poised to Disrupt the Healthcare Market by 2030
The biggest mistake investors make with healthcare stocks is assuming the future will look like the past: incremental…
FDA testing speedier drug development with real-time clinical trials
WASHINGTON — The Food and Drug Administration on Tuesday announced efforts to make clinical trials more efficient, starting…
Erasca touts strong early results in pancreatic and lung cancer therapy trial
Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall…
The podcaster behind ‘Drug Story’ on public-health storytelling
Below is a lightly edited, AI-generated transcript of the “First Opinion Podcast” interview with Thomas Goetz. Be sure…
20 Years Of Priority Review Vouchers, A Tool For Spurring Needed Drugs
Collection of sandflies, which can transmit river blindness Universal Images Group via Getty Images Occasionally I’ll go watch…
Eli Lilly’s $3.25B acquisition of Kelonia Therapeutics caps startup’s tortuous ride
Eli Lilly is spending $3.25 billion to acquire Kelonia Therapeutics, a small biotech company developing cell therapies for…
Medicare, Travere, Cochrane, Roche, Eli Lilly: Readout Newsletter
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter…
Race for AI-developed drugs heats up: Wegovy-maker Novo Nordisk ties up with OpenAI after rival Eli Lilly seals deal
Danish drugmaker Novo Nordisk on Tuesday announced that it is collaborating with ChatGPT’s parent company, OpenAI, to bring…
Gilead to buy cancer biotech Tubulis for more than $3B
Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at…
Replimune skin cancer drug that became FDA flashpoint is rejected again
The Food and Drug Administration on Friday rejected — again — an experimental treatment for advanced skin cancer…